Work

Hematopoietic Stem Cell Transplantation (HSCT) for Acute Lymphoblastic Leukemia (ALL) in First Remission (CR1): A Single-Institution Retrospective Cohort Study Demonstrating Excellent Event-Free (EFS) and Overall Survival (OS)

Year: 2016

Type: article

Abstract: Most children with newly-diagnosed ALL are cured with chemotherapy alone; however, a subset of patients with very high-risk disease features are referred for HSCT in CR1. An evidence-based review by the American Society for Blood and Marrow Transplantation (ASBMT) recommends allogeneic HSCT in CR1 for children with primary induction failure and to consider HSCT for children with low hypodiploidy (<44 chromosomes) or persistent minimal residual disease (MRD), though limited data exist to support demonstrable benefit to HSCT in this population.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2015.11.651

Authors: Karen L. Bride, Jason L. Freedman, Nancy J. Bunin, Stephen P. Hunger, Susan R. Rheingold, Alix E. Seif

Institutions: Children's Hospital of Philadelphia, University of Pennsylvania

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650